Table 5.

Comparison of fold changes in response to PPV-23 vaccine between asthmatics and non-asthmatics

	Subjects with asthma		Subjects without asthma
Serotype	Median	IQR	Median	IQR	P-value^U
1	4.48^***	1.75–9.67	5.81^***	3.22–20.65	0.147
2	2.15^**	1.14–25.98	4.41^***	1.76–7.62	0.335
3	2.03^***	1.45–4.69	3.90^***	1.65–10.75	0.153
4	7.71^***	2.70–13.43	6.50^***	2.00–50.93	0.748
5	1.87^**	1.09–3.99	1.64^***	1.17–3.47	0.822
6B	3.82^***	1.20–6.18	2.39^***	1.23–7.30	0.632
7F	1.08	0.98–1.32	1.25^***	0.97–1.85	0.201
8	1.76^***	1.40–4.44	4.25^***	1.39–9.36	0.167
9	1.58^**	1.16–3.17	4.10^***	1.46–9.34	0.016
9V	2.02^***	1.29–3.02	2.95^***	1.44–6.40	0.169
10A	1.24^**	0.99–2.72	1.26^***	1.08–3.23	0.725
11A	3.93^***	1.62–8.39	4.45^***	2.66–10.72	0.463
12F	1.43^**	1.00–3.79	2.12^***	1.15–4.75	0.353
14	2.51^***	1.35–7.83	2.57^***	1.10–10.71	0.681
15B	6.12^***	2.52–12.99	10.06^***	3.50–32.59	0.143
17F	2.10^*	1.15–3.48	2.05^***	1.31–6.62	0.464
18C	10.82^***	6.17–17.93	8.85^***	3.75–20.20	0.424
19A	3.21^***	1.18–14.4	4.46^***	1.59–14.18	0.560
19F	1.81^***	1.39–8.17	2.47^***	1.31–7.72	1.0
20	2.53^**	1.23–4.74	3.05^***	1.16–11.06	0.259
22F	1.07	1.0–1.32	1.16^*	0.98–1.63	0.424
23F	1.0	0.94–1.17	1.21^**	0.99–2.51	0.023
33F	2.03^***	1.01–8.16	4.13^***	1.97–11.42	0.067

Superscript asterisk denotes statistical significance of fold change (i.e. pre-vaccine to post vaccine with a group using paired Wilcoxon Signed-Rank Test).

P<0.05,

^**

P<0.01,

^***

P<0.001

IQR: Inter-quartile range between 25^th and 75^th percentile.

P-value in the last column is comparison between groups (non-asthmatics vs. asthmatics).

Unadjusted.